The Chinese CTONG trial compared adjuvant TKI therapy with gefitinib for two years to the standard of care with 4 cycles of cisplatin/vinorelbine in patients with EGFR-mutated lung cancer. This evidence concerns the gene EGFR and lung carcinoma.